JP2022529741A5 - - Google Patents

Info

Publication number
JP2022529741A5
JP2022529741A5 JP2021563069A JP2021563069A JP2022529741A5 JP 2022529741 A5 JP2022529741 A5 JP 2022529741A5 JP 2021563069 A JP2021563069 A JP 2021563069A JP 2021563069 A JP2021563069 A JP 2021563069A JP 2022529741 A5 JP2022529741 A5 JP 2022529741A5
Authority
JP
Japan
Prior art keywords
approximately
cells
cell
concentration
stimulant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021563069A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022529741A (ja
JP7650818B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/029722 external-priority patent/WO2020219812A1/en
Publication of JP2022529741A publication Critical patent/JP2022529741A/ja
Publication of JP2022529741A5 publication Critical patent/JP2022529741A5/ja
Application granted granted Critical
Publication of JP7650818B2 publication Critical patent/JP7650818B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021563069A 2019-04-26 2020-04-24 同種car t細胞を製造する方法 Active JP7650818B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962839449P 2019-04-26 2019-04-26
US62/839,449 2019-04-26
PCT/US2020/029722 WO2020219812A1 (en) 2019-04-26 2020-04-24 Methods of manufacturing allogeneic car t cells

Publications (3)

Publication Number Publication Date
JP2022529741A JP2022529741A (ja) 2022-06-23
JP2022529741A5 true JP2022529741A5 (https=) 2023-05-01
JP7650818B2 JP7650818B2 (ja) 2025-03-25

Family

ID=70617287

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021563069A Active JP7650818B2 (ja) 2019-04-26 2020-04-24 同種car t細胞を製造する方法

Country Status (11)

Country Link
US (2) US12163153B2 (https=)
EP (1) EP3959305A1 (https=)
JP (1) JP7650818B2 (https=)
KR (1) KR20220004028A (https=)
CN (1) CN113748201A (https=)
AU (1) AU2020261411B2 (https=)
BR (1) BR112021021349A2 (https=)
CA (1) CA3132509A1 (https=)
IL (1) IL287562B2 (https=)
MX (1) MX2021013005A (https=)
WO (1) WO2020219812A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3158133A1 (en) * 2020-04-28 2021-11-04 Lyell Immunopharma, Inc. Methods for culturing cells
CN115039763A (zh) * 2022-07-15 2022-09-13 北京大学第三医院(北京大学第三临床医学院) 一种免疫细胞冻存液
CN118272305B (zh) * 2024-04-29 2025-04-08 深圳泽医细胞治疗集团有限公司 一种免疫细胞的培养基及其应用

Family Cites Families (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
US4975278A (en) 1988-02-26 1990-12-04 Bristol-Myers Company Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells
EP0368684B2 (en) 1988-11-11 2004-09-29 Medical Research Council Cloning immunoglobulin variable domain sequences.
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US6319494B1 (en) 1990-12-14 2001-11-20 Cell Genesys, Inc. Chimeric chains for receptor-associated signal transduction pathways
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
GB9114948D0 (en) 1991-07-11 1991-08-28 Pfizer Ltd Process for preparing sertraline intermediates
FI941572A7 (fi) 1991-10-07 1994-05-27 Oncologix Inc Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenete lmä
IL104570A0 (en) 1992-03-18 1993-05-13 Yeda Res & Dev Chimeric genes and cells transformed therewith
US5830462A (en) 1993-02-12 1998-11-03 President & Fellows Of Harvard College Regulated transcription of targeted genes and other biological events
US5834266A (en) 1993-02-12 1998-11-10 President & Fellows Of Harvard College Regulated apoptosis
US5869337A (en) 1993-02-12 1999-02-09 President And Fellows Of Harvard College Regulated transcription of targeted genes and other biological events
US20030036654A1 (en) 1994-08-18 2003-02-20 Holt Dennis A. Synthetic multimerizing agents
US5827642A (en) 1994-08-31 1998-10-27 Fred Hutchinson Cancer Research Center Rapid expansion method ("REM") for in vitro propagation of T lymphocytes
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US6610833B1 (en) 1997-11-24 2003-08-26 The Institute For Human Genetics And Biochemistry Monoclonal human natural antibodies
DK1034298T3 (da) 1997-12-05 2012-01-30 Scripps Research Inst Humanisering af murint antistof
US6797514B2 (en) 2000-02-24 2004-09-28 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
US6867041B2 (en) 2000-02-24 2005-03-15 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
KR20030032922A (ko) 2000-02-24 2003-04-26 싸이트 테라피스 인코포레이티드 세포의 동시 자극 및 농축
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
CA2430013C (en) 2000-11-30 2011-11-22 Medarex, Inc. Transgenic transchromosomal rodents for making human antibodies
EP1740615B1 (en) 2004-03-31 2014-11-05 Genentech, Inc. Humanized anti-tgf-beta antibodies
US20100035282A1 (en) 2005-08-03 2010-02-11 Maria Chiara Bonini Use of common gamma chain cytokines for the visualization, isolation and genetic modification of memory t lymphocytes
PT1956080E (pt) 2005-08-08 2011-12-30 San Raffaele Centro Fond Uso de il-7 e il-15 para a modificação genética de linfócitos t da memória
WO2007137300A2 (en) 2006-05-23 2007-11-29 Bellicum Pharmaceuticals, Inc. Modified dendritic cells having enhanced survival and immunogenicity and related compositions and methods
WO2011057124A1 (en) * 2009-11-06 2011-05-12 Transtarget, Inc. Polyclonal bispecific antibody compositions and method of use
CA2797356C (en) 2010-04-26 2020-12-29 Novartis Ag Improved cell culture medium
US9089520B2 (en) 2010-05-21 2015-07-28 Baylor College Of Medicine Methods for inducing selective apoptosis
PH12013501201A1 (en) 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
AU2012209103B2 (en) 2011-01-26 2015-12-03 Takeda Pharmaceutical Company Limited Methods and compositions for the synthesis of multimerizing agents
US9987308B2 (en) 2011-03-23 2018-06-05 Fred Hutchinson Cancer Research Center Method and compositions for cellular immunotherapy
JP2014511704A (ja) 2011-04-13 2014-05-19 イミュニカム・エイビイ T細胞のプライミングのための方法
GB201206559D0 (en) 2012-04-13 2012-05-30 Ucl Business Plc Polypeptide
US20140170748A1 (en) 2012-12-14 2014-06-19 DePuy Synthes Products, LLC Nutrient Enriched Media for hUTC Growth
DK2956175T3 (da) 2013-02-15 2017-11-27 Univ California Kimærisk antigenreceptor og fremgangsmåder til anvendelse deraf
CA2905352A1 (en) 2013-03-14 2014-09-25 Bellicum Pharmaceuticals, Inc. Methods for controlling t cell proliferation
WO2014165707A2 (en) * 2013-04-03 2014-10-09 Memorial Sloan-Kettering Cancer Center Effective generation of tumor-targeted t-cells derived from pluripotent stem cells
HK1221260A1 (zh) 2013-06-24 2017-05-26 Celgene Corporation 扩增t细胞的方法
EP3925618A1 (en) 2013-07-29 2021-12-22 2seventy bio, Inc. Multipartite signaling proteins and uses thereof
US10233425B2 (en) 2013-09-16 2019-03-19 The Trustees Of The University Of Pennsylvania CD137 enrichment for efficient tumor infiltrating lymphocyte selection
EP3087101B1 (en) 2013-12-20 2024-06-05 Novartis AG Regulatable chimeric antigen receptor
US10934346B2 (en) 2014-02-14 2021-03-02 Bellicum Pharmaceuticals, Inc. Modified T cell comprising a polynucleotide encoding an inducible stimulating molecule comprising MyD88, CD40 and FKBP12
US20170274014A1 (en) 2014-07-21 2017-09-28 Jennifer Brogdon Combinations of low, immune enhancing, doses of mtor inhibitors and cars
EP3018200A1 (en) 2014-11-07 2016-05-11 Fondazione Matilde Tettamanti e Menotti de Machi Onlus Improved method for the generation of genetically modified cells
RU2021118125A (ru) 2014-12-29 2022-04-06 Новартис Аг Способы получения экспрессирующих химерный антигенный рецептор клеток
BR112017013981A2 (pt) 2015-01-26 2018-01-02 Cellectis receptores antigênicos quiméricos com uma única cadeia específicos anti-cll1 (sccars) para imunoterapia de câncer
EP3297642B1 (en) * 2015-05-22 2019-09-11 STCube & Co., Inc. Screening methods for targets for cancer therapy
EP3322424B1 (en) 2015-07-16 2023-10-11 Yeda Research and Development Co., Ltd. Use of anti third party central memory t cells
CA2992551A1 (en) 2015-07-21 2017-01-26 Novartis Ag Methods for improving the efficacy and expansion of immune cells
KR20180063320A (ko) 2015-10-20 2018-06-11 카이트 파마 인코포레이티드 T 세포 요법을 위한 t 세포를 제조하는 방법
US11020429B2 (en) 2015-11-05 2021-06-01 Juno Therapeutics, Inc. Vectors and genetically engineered immune cells expressing metabolic pathway modulators and uses in adoptive cell therapy
US11479755B2 (en) 2015-12-07 2022-10-25 2Seventy Bio, Inc. T cell compositions
RU2018127657A (ru) 2015-12-30 2020-01-31 Новартис Аг Виды терапии на основе иммуноэффекторных клеток с улучшенной эффективностью
JP7019578B2 (ja) 2015-12-30 2022-02-15 セルジーン コーポレイション Tリンパ球の産生方法及びそれにより産生されるtリンパ球
JP7653759B2 (ja) 2016-01-20 2025-03-31 フェイト セラピューティクス,インコーポレイテッド 養子免疫療法における免疫細胞調節のための組成物および方法
CA3036926C (en) * 2016-09-30 2022-05-31 Poseida Therapeutics, Inc. Modified stem cell memory t cells, methods of making and methods of using same
US20200095547A1 (en) 2016-12-02 2020-03-26 Darya ALIZADEH Methods for manufacturing t cells expressing of chimeric antigen receptors and other receptors
US10329543B2 (en) * 2017-10-23 2019-06-25 Poseida Therapeutics, Inc. Modified stem cell memory T cells, methods of making and methods of using same
US12258580B2 (en) * 2017-11-01 2025-03-25 Juno Therapeutics, Inc. Process for generating therapeutic compositions of engineered cells
CN112262212B (zh) * 2018-04-24 2024-07-12 美国卫生和人力服务部 使用羟基柠檬酸和/或其盐产生t细胞群体的方法
AU2019335014A1 (en) * 2018-09-05 2021-03-25 Poseida Therapeutics, Inc. Allogeneic cell compositions and methods of use

Similar Documents

Publication Publication Date Title
US20250215396A1 (en) Compositions and methods for immune cell modulation in adoptive immunotherapies
US20240263135A1 (en) Compositions and methods for immune cell modulation in adoptive immunotherapies
JP7653759B2 (ja) 養子免疫療法における免疫細胞調節のための組成物および方法
US12036241B2 (en) Compositions and methods for immune cell modulation in adoptive immunotherapies
JP2022529741A5 (https=)
JP2016509839A5 (https=)
IL274293B2 (en) Process for generating therapeutic compositions of engineered cells
JP2012521215A5 (https=)
JP2019523001A5 (https=)
TWI224137B (en) A process for proliferating natural killer cell, method for determining cytotoxic activity same, and therapeutic agent of tumor
JP2022522231A5 (https=)
KR20080111054A (ko) 신규한 인간 t세포 집단
CN116004533A (zh) iNKT细胞的激活扩增方法及其培养基组合
JP2022520302A5 (https=)
JP2024523332A5 (https=)
JP2024515064A5 (https=)
RU2021134179A (ru) Способы получения аллогенных t-клеток с car
WO2020251046A1 (ja) 医薬組成物
WO2026096605A1 (en) Methods for activation and expansion of gamma delta t cells
KHAPHI et al. ROLE OF CD117 AND MAST CELLS IN PERIODONTAL DISEASES: HISTOLOGICAL AND IMMUNOHISTOCHEMICAL STUDY
HK40092133A (zh) 用来在过继性免疫疗法中进行免疫细胞调节的组合物和方法
Hudspeth et al. Graft-versus-brain tumor effect in a child with anaplastic astrocytoma after cord blood transplantation for therapy-related leukemia